New Ways to Target B-Cell Blood Cancers
Targeting GSK3B in refractory B-cell malignancies
This research explores a new way to stop the growth of B-cell blood cancers, like certain types of leukemia and lymphoma, by targeting a specific protein.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11126737 on NIH RePORTER |
What this research studies
Our bodies have proteins that control cell growth, and sometimes these go wrong in cancer. This project looks at a protein called GSK3E, which helps manage another protein called E-catenin. In B-cell blood cancers, we found that too much E-catenin can actually be harmful to cancer cells, making them die. Unlike other cancers, B-cell cancers seem to depend on GSK3E to keep E-catenin levels in check. We are exploring how to use this unique weakness to develop new treatments.
Who could benefit from this research
Good fit: This research is focused on understanding and treating B-cell malignancies, including types of leukemia and lymphoma that are difficult to treat.
Not a fit: Patients with solid tumors or other types of blood cancers not involving B-cells may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this work could lead to new treatment options for patients with B-cell blood cancers that have not responded to other therapies.
How similar studies have performed: While the specific approach for B-cell malignancies is novel, similar inhibitors targeting GSK3E are already being tested in clinical trials for other diseases.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Muschen, Markus — Yale University
- Study coordinator: Muschen, Markus
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.